Ex Parte Sakata

6 Cited authorities

  1. Pfizer v. Apotex

    480 F.3d 1348 (Fed. Cir. 2007)   Cited 380 times   7 Legal Analyses
    Holding the district court clearly erred when it failed to consider relevant prior art
  2. In re Soni

    54 F.3d 746 (Fed. Cir. 1995)   Cited 91 times   2 Legal Analyses
    Finding "substantially improved results" to overcome obviousness when the 50-fold improvement in tensile strength was much greater than would have been predicted
  3. Application of Lindner

    457 F.2d 506 (C.C.P.A. 1972)   Cited 18 times
    Involving dispersant compositions designed to emulsify solutions such as insecticide
  4. In re Dill

    604 F.2d 1356 (C.C.P.A. 1979)   Cited 3 times

    Appeal No. 79-518. August 9, 1979. Robert A. Felsman, Fort Worth, Tex., atty. of record, for appellants; Dennison, Dennison, Mesorole Pollack, Arlington, Va., of counsel. Joseph F. Nakamura, Washington, D.C., for the Commissioner of Patents; Fred W. Sherling, Associate Solicitor, Washington, D.C., of counsel. Appeal from the Patent and Trademark Office Board of Appeals. Before MARKEY, Chief Judge, RICH, BALDWIN, and MILLER, Judges, and PENN, Judge. The Honorable John G. Penn, United States District

  5. Section 103 - Conditions for patentability; non-obvious subject matter

    35 U.S.C. § 103   Cited 6,130 times   479 Legal Analyses
    Holding the party seeking invalidity must prove "the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains."
  6. Section 6 - Patent Trial and Appeal Board

    35 U.S.C. § 6   Cited 186 times   63 Legal Analyses
    Giving the Director authority to designate "at least 3 members of the Patent Trial and Appeal Board" to review "[e]ach appeal, derivation proceeding, post-grant review, and inter partes review"